Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 12, 2021- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31,...
Jan 11, 2021Peer-reviewed clinical study published in the Journal of the Association for Vascular Access supports the use of midline catheters as an effective method for blood collection while reducing number of venipuncturesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of the first-ever...
-
Dec 22, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast....
Dec 18, 2020BD earns certificate under Annex IX Chapter I & IIIBritish Standards Institution (BSI), the national standards body for the United Kingdom and a designated European Notified Body, today announces it has certified its first group of products to the...
Dec 16, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1...
-
Dec 14, 2020
FRANKLIN LAKES, N.J. (Dec. 14, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its inaugural cybersecurity annual report,...
Dec 9, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD...
Dec 2, 2020Investment includes new manufacturing facility in EuropeBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade...
-
Nov 24, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend...
Nov 23, 2020Reports Generated by BD Synapsys™ 3.84 Informatics Solution Simplify Mandatory Public Health ReportingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be...
-
Nov 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on...
-
Nov 12, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held...
Nov 10, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Nov 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel...
Nov 9, 2020FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Paddy O’Brien to worldwide...
Nov 9, 2020FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expanded role of Tony Ezell as president of...
-
Nov 5, 2020- Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30,...
Nov 2, 2020The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-NovemberBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid,...
Oct 22, 2020Patrick Kaltenbach appointed chief technology officer
Dave Hickey promoted to president, Life Sciences segmentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology...
Oct 21, 2020CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR...
Oct 16, 2020BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes brings time-tested immune assessment solution to European clinicians treating COVID-19 patientsEYSINS, Switzerland, Oct. 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark and European availability of a...
Oct 7, 2020Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare accessBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships,...
Oct 6, 2020Four of every ten women received inappropriate treatmentFRANKLIN LAKES, N.J., October 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the publication of an investigator-initiated study...
Oct 5, 2020BD FACSDuet™ Sample Preparation System, now available in the U.S., as the first fully automated sample-to-answer solution when integrated with the BD FACSLyric™ Flow CytometerBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
-
Oct 2, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday,...
Sep 30, 2020SARS-CoV-2 Assay for BD Veritor™ Plus System to be available in Europe by end of OctoberBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
Sep 24, 2020FRANKLIN LAKES, N.J. (Sept. 24, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: Today, the Attorneys...
Sep 23, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Sep 21, 2020Three Recalls Designated as Class I by FDA; One Designated as Class II
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on previously announced voluntary recalls of the BD Alaris™ System. Three of...
Sep 15, 2020FRANKLIN LAKES, N.J. (Sept. 15, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD is aware that a...
Sep 9, 2020Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen testsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™...
-
Aug 31, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual investor healthcare conferences:...
Aug 24, 2020FRANKLIN LAKES, N.J., Aug. 24, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Eric Borin to worldwide...
-
Aug 20, 2020Majority of June 30 Recall Designated as Class I Recall by FDA
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on a previously announced voluntary recall of the BD Alaris™ System. Three...
Aug 17, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice...
-
Aug 13, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on...
Aug 10, 2020BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over...
-
Aug 7, 2020
BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on June 23, 2020 for specified catalog numbers of the ChloraPrep™ 3 mL applicator...
-
Aug 6, 2020- As reported, revenues of $3.855 billion decreased 11.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020....
-
Aug 3, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and...
Jul 30, 2020Capital investments will enable U.S. manufacturing of 8 million BD Veritor™ brand SARS-CoV-2 tests per monthBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the...
Jul 28, 2020BD Kiestra™ InoqulA system is available in Europe (CE marked)FRANKLIN LAKES, N.J., July 28, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) of the new...
-
Jul 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on...
Jul 22, 2020BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food...
Jul 21, 2020U.S. Orders 140 Million Additional Devices; Canada Orders 37 Million Additional DevicesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada...
Jul 17, 2020WARWICK, R.I. (July 17, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Kevin Kelly to worldwide...
Jul 15, 2020Government committed to use of BD Veritor™ Plus System and 15-minute SARS-CoV-2 test kitsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD...
Jul 8, 2020Company Finalizes Initial Pandemic Order for 50 Million Injection Devices to Support Operation Warp Speed Vaccination ProgramBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
Jul 7, 2020New BD PurPrep™ skin preparation is the only commercially available PVP-I antiseptic skin preparation with sterile solution in the U.S.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile...
Jul 6, 2020- Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settingsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization...